ZSCAN1 and neoplasm: The tumor-initiating capacity of ZSCAN1-overexpressing BCSLCs was also significantly decreased versus control BCSLCs (Figure 2G, 3 replicates, P < 0.001 in MCF-7), as identified by an in vivo limiting dilution assay.